in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
in vitro PHARMACOLOGY 2011 CATALOG - Cerep
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
71<br />
seroton<strong>in</strong> ❚<br />
5-HT 2B - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 1333<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
ExpresS Profile<br />
High-throughput profile<br />
BioPr<strong>in</strong>t ® profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
[ 125 I](±)DOI (0.2 nM)<br />
0.2 nM<br />
(±)DOI (1 µM)<br />
(±)DOI (IC 50 : 5 nM)<br />
Choi, D.S. et al. (1994) FEBS Lett., 352: 393-399.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-12 -11 -10 -9 -8 -7 -6<br />
log [drug] (M)<br />
(±)DOI<br />
seroton<strong>in</strong><br />
5-methoxytryptam<strong>in</strong>e<br />
BW 723C86<br />
<strong>Cerep</strong><br />
services<br />
<br />
Receptors<br />
[GPCRs]<br />
5-HT 2B<br />
cellul ar<br />
Ref. 3344<br />
Ref. 3345<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
Agonist effect<br />
Antagonist effect<br />
Cellular functional GPCR profile<br />
Source<br />
human recomb<strong>in</strong>ant (CHO cells)<br />
Measured product IP 1<br />
Detection method HTRF<br />
Agonist effect Control seroton<strong>in</strong> (1 µM)<br />
Reference seroton<strong>in</strong> (EC 50 : 10.1 nM)<br />
Antagonist effect Stimulant seroton<strong>in</strong> (30 nM)<br />
Reference SB 206553 (IC 50 : 28.4 nM)<br />
Porter, R.H.P. et al. (1999) Brit. J. Pharmacol., 128: 13-20.<br />
<br />
<br />
<br />
-10 -9 -8 -7 -6 -5 -4 -3<br />
-11 -10 -9 -8 -7 -6 -5 -4 -3<br />
<br />
<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4<br />
-13 -12 -11 -10 -9 -8 -7 -6 -5<br />
<br />
<br />
-6<br />
-10 -9 -8 -7<br />
<br />
<br />
<br />
<br />
-5 -4<br />
-10 -9 -8 -7 -6 <br />
<br />
<br />
<br />
<br />
<br />
-6 -5 -4 -12 -11 -10 -9 -8 -7 -3<br />
-11 -10 -9 -8 -7 -6 -5<br />
-12<br />
Ion<br />
channels<br />
Transporters<br />
-11 -10 -9 -8 -7 -6 -5 -4<br />
5-HT 2B<br />
tissue<br />
Ref. 0333<br />
Q 4 weeks<br />
Source<br />
rat stomach fundus<br />
Agonist 5-CT (pD 2 = 7.5)<br />
Antagonist methiothep<strong>in</strong> (pA 2 = 8.4)<br />
Test concentrations 3 concentrations, n=2 (2 tissues)<br />
for both activities<br />
[Solvent] must be kept ≤ 0.1%<br />
Baxter, G.S. et al. (1994) Brit. J. Pharmacol., 112: 323-331.<br />
tension (% of max.)<br />
<br />
<br />
<br />
100<br />
<br />
<br />
50<br />
<br />
<br />
methiothep<strong>in</strong><br />
none<br />
0.1 µM<br />
0<br />
1 µM<br />
10 µM<br />
-9 -8 -7 -6 -5 -4<br />
log [agonist] (M)<br />
K<strong>in</strong>ases<br />
Epigenetic &<br />
DNA-related<br />
enzymes<br />
5-HT 2C - antagonist radioligand<br />
Source<br />
human recomb<strong>in</strong>ant (HEK-293 cells)<br />
Ligand<br />
[ 3 H]mesulerg<strong>in</strong>e (1 nM)<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Kd<br />
0.5 nM<br />
Ref. 0137<br />
Non specific RS 102221 (10 µM)<br />
Q 3 weeks<br />
Reference RS 102221 (IC 50 : 3.1 nM)<br />
Included <strong>in</strong>:<br />
High-throughput profile<br />
Stam, N.J. et al. (1994) Eur. J. Pharmacol., 269: 339-348.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100<br />
50<br />
0<br />
-12 -11 -10 -9 -8 -7 -6 -5<br />
log [drug] (M)<br />
RS 102221<br />
Ro 600175<br />
seroton<strong>in</strong><br />
ketanser<strong>in</strong><br />
Other<br />
enzymes<br />
Specialized<br />
cellular<br />
assays<br />
5-HT 2C - agonist radioligand<br />
b<strong>in</strong>d<strong>in</strong>g<br />
Ref. 1003<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
BioPr<strong>in</strong>t ® profile<br />
Organ safety profile<br />
Source<br />
Ligand<br />
Kd<br />
Non specific<br />
Reference<br />
human recomb<strong>in</strong>ant (HEK-293 cells)<br />
[ 125 I](±)DOI (0.1 nM)<br />
0.9 nM<br />
(±)DOI (10 µM)<br />
(±)DOI (IC 50 : 0.38 nM)<br />
Bryant, H.U. et al. (1996) Life Sci., 15: 1259-1268.<br />
specific b<strong>in</strong>d<strong>in</strong>g (% of control)<br />
100 -10 -9 -8 -7 -6 -5 -4 -3<br />
-11 -10 -9 -8 -7 -6 -5 -4 -3<br />
-12 -11 -10 -9 -8 -7 -6 -5 -4<br />
50<br />
-13 -12 -11 -10 -9 -8 -7 -6 -5<br />
-9 -8 -7 -6<br />
-10<br />
(±)DOI<br />
seroton<strong>in</strong><br />
RS 102221<br />
-10 -9 -8 -7 -6 -5 -4<br />
0<br />
Ro 600175<br />
-11 - 10 -9 -8 -7 -6<br />
-11 -10 -8 -6 -5 -12 -9 -7 -4 -3<br />
log [drug] (M)<br />
-10 -9 -8 -7 -12 -11 -6 -5<br />
-11 -10 -7 -6 -5 -4<br />
-9 -8<br />
Standard<br />
profiles<br />
Test<strong>in</strong>g<br />
conditions<br />
5-HT 2C<br />
cellul ar<br />
Ref. 3197<br />
Ref. 3199<br />
Q 3 weeks<br />
Included <strong>in</strong>:<br />
Agonist effect<br />
Antagonist effect<br />
Cellular functional GPCR profile<br />
Source<br />
human recomb<strong>in</strong>ant (HEK-293 cells)<br />
Measured product IP 1<br />
Detection method HTRF<br />
Agonist effect Control seroton<strong>in</strong> (1 µM)<br />
Reference seroton<strong>in</strong> (EC 50 : 1.81 nM)<br />
Antagonist effect Stimulant seroton<strong>in</strong> (30 nM)<br />
Reference SB 206553 (IC 50 : 20.2 nM)<br />
Porter, R.H.P. et al. (1999) Brit. J. Pharmacol., 128: 13-20.<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
❚ For 5-HT 3 assays, see "OTHER RECEPTORS", page 90<br />
Order<strong>in</strong>g<br />
<strong>in</strong>formation<br />
Assay list<br />
& <strong>in</strong>dex